Comparative tolerability of therapies for Cytomegalovirus retinitis

Drug Safety

Volumn 21, Issue 3, 1999, Pages 203-224

  Walmsley, Sharon ^a,b,d   Tseng, Alice ^a,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; AMINOGLYCOSIDE; AMPHOTERICIN B; ANTIVIRUS AGENT; BENZIMIDAZOLE; CIDOFOVIR; DAPSONE; FLUCYTOSINE; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; GANCICLOVIR DERIVATIVE; IMIPENEM; LOBUCAVIR; PENTAMIDINE; PRIMAQUINE; PROBENECID; PYRIMETHAMINE; TRIMETREXATE; UNCLASSIFIED DRUG; VALGANCICLOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ASTHENIA; CENTRAL VENOUS CATHETER; CONFUSION; CYTOMEGALIC INCLUSION BODY DISEASE; DIARRHEA; DRUG CHOICE; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; FEVER; GRANULOCYTOPENIA; HALLUCINATION; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; IRITIS; LIVER TOXICITY; MUSCLE HYPOTONIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RETINA DETACHMENT; RETINITIS; REVIEW; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS RETINITIS; FOSCARNET; GANCICLOVIR; HIV INFECTIONS; HUMANS;

EID: 0032886087     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199921030-00005     Document Type: Review

References (142)

1. Pertel P, Hirschtick R, Phair J, et al. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr 1992; 5: 1069-74
2. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349: 1443-5
3. Baril L, Jouan M, Caumes E, et al. The impact of highly active anti-retroviral therapy on the incidence of CMV disease in AIDS patients [abstract I-31]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1997 Sep 28-Oct 1, Toronto: 248
4. Brodt HR, Kamps BS, Gute P, et al. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997; 11: 1731-8
5. Moore RD, Keruly JC, Chaisson RE. Decline in CMV and other opportunistic disease with combination antiretroviral therapy [abstract 184]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago (IL): 113
6. Walsh JC, Jones CD, Barnes EA, et al. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors. AIDS 1998; 12: 613-8
7. Whitcup SM, Fortin E, Nussenblatt RB, et al. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis [letter]. JAMA 1997; 277 (19): 1519-20
8. Macdonald JC, Torriani FJ, Morse LS, et al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998; 177 (5): 1182-7
9. Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998; 177 (4): 1080-3
10. Cytovene Product Monograph. Hoffman-LaRoche Limited. Mississauga (ON), 1995
11. Gilead Sciences Inc. Vistide Product Monograph. Foster City (CA), 1996
12. Diaz-Llopis M, Chipont E, Sanchez S, et al. Intravitreal foscarnet for cytomegalovirus retinits in a patient with acquired immunodeficiency syndrome. Am J Ophthalmol 1992; 114: 742-7
13. Tseng AL, Foisy M. The role of ganciclovir for the management of cytomegalovirus retinitis in HIV patients: pharmacological review and update on new developments. Can J Infect Dis 1996; 7 (3): 183-94
14. Pearson PA, Jaffe GJ, Ashton P. Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome [letter]. Am J Ophthalmol 1993; 115 (5): 686-8
15. Foscavir Product Monograph. Astra Pharmaceutical Products Inc. Sodertalje, Sweden, 1995
16. Tseng AL, Foisy MM. Management of drug interactions in patients with HIV. Ann Pharmacother 1997; 31: 1040-58
17. Palestine AG, Stevens Jr G, Lane HC, et al. Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine. Am J Opthalmol 1986; 101 (1): 95-101
18. Collaborative DHPG Treatment Study Group. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med 1986; 314 (13): 801-5
19. Holland GN, Sidikaro Y, Kreiger AE, et al. Treatment of cytomegalovirus retinopathy with ganciclovir. Ophthalmology 1987; 94 (7): 815-23
20. Jabs DA, Newman C, De Bustros S, et al. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 1987; 94 (7): 824-30
21. Orellana J, Teich SA, Friedman AH, et al. Combined short- and long-term therapy for the treatment of cytomegalovirus retinitis using ganciclovir (BW B759U). Ophthalmology 1987; 94 (7): 831-8
22. Laskin OL, Cederberg DM, Mills J, et al. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med 1987; 83 (2): 201-7
23. Jacobson MA, JJ OD, Porteous D, et al. Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history, and response to ganciclovir therapy. Q J Med 1988; 67 (254): 473-86
24. Buhles Jr WC, Mastre BJ, Tinker AJ, et al. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev Infect Dis 1988; 10 Suppl. 3: S495-506
25. Masur H, Lane HC, Palestine A, et al. Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men. Ann Intern Med 1986; 104 (1): 41-4
26. Jacobson MA, O'Donnell JJ, Brodie HR, et al. Randomised prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis. J Med Virol 1988; 25 (3): 339-49
27. Holland GN, Sakamoto MJ, Hardy D, et al. Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome: use of the experimental drug 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Arch Ophthalmol 1986; 104 (12): 1794-800
28. Henderly DE, Freeman WR, Causey DM, et al. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology 1987; 94 (4): 425-34
29. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326 (4): 213-20
30. Spector SA, Weingeist T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis 1993; 168 (3): 557-63
31. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995; 333 (10): 615-20
32. Moses A, Mortimer C, Salit I, et al. Cytomegalovirus (CMV) retinitis in an HIV clinical setting: tolerance and responses to systematic and local antiviral therapies [abstract Th.B.4195]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver (BC): 284
33. Moses A, Mortimer C, Salit I, et al. Efficacy of therapy for cytomegalovirus (CMV) in AIDS [abstract 165]. 3rd National Conference on Human Retrovirus and Related Infections; 1996 Jan 28-Feb 1; Washington (DC): 83
34. Arevalo JF, Gonzalez C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995; 172 (4): 951-6
35. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Arch Intern Med 1995; 155 (1): 65-74
36. Kitano K, Abboud CN, Ryan DH, et al. Macrophage-active colony-stimulating factors enhance human immunodeficiency virus type I infection in bone marrow stem cells. Blood 1991; 77 (8): 1699-705
37. Pluda JM, Yarchoan R, Smith PD, et al. Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leakopenic patients with severe human immunodeficiency virus infection. Blood 1990; 76 (3): 463-72
38. Skowron G, Stein D, Drusano G, et al. Safety and anti-HIV effect of GM-CSF in patients on highly active anti-retroviral therapy [abstract 615]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago (IL)195
39. Hardy D, Spector S, Polsky B, et al. Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. Eur J Clin Microbiol Infect Dis 1994; 13 Suppl. 2: S34-40
40. Kumar PN, Tamari M, Rich W, et al. A prospective, randomized, parallel-group, single-center, phase II study comparing the safety and efficacy of 10/5, 10/10, and 15/15 mg/kg/day ganciclovir induction/maintenance therapy with filgrastim support in delaying or preventing the progression of CMV retinitis in patients with AIDS [abstract H-59b]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto (ON): 224
41. Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis 1995; 171 (6): 1431-7
42. The Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS 1995; 9 (5): 471-7
43. Squires KE. Oral ganciclovir for cytomegalovirus retinitis in patients with AIDS; results of two randomized studies. AIDS 1996; 10 Suppl. 4: S13-8
44. Lalezari J, Friedberg D, Bisset J, et al. A comparison of the safety and efficacy of 3g, 4.5g, and 6g doses of oral ganciclovir versus IV ganciclovir for maintenance treatment of CMV retinitis [abstract ThB305]. XI International Conference on AIDS; 1996 July 7-12; Vancouver (BC): 226
45. Ward-Able C, Phillips P, Tsoukas CM. The use of oral ganciclovir in the treatment of cytomegalovirus retinitis in patients with AIDS. Can Med Assoc J 1996; 154 (3): 363-8
46. Centers for Disease Control and Prevention. Draft Version of the 1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with HIV. 1999 May 14; Bethesda (MD)
47. Deayton J, Wilson P, Sabin C, et al. Changes in the natural history of CMV retinitis following the introduction of highly active antiretroviral therapy (HAART) [abstract I-270]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego (CA): 448
48. Sullivan SD, Mozaffari E, Johnson ES, et al. An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients. Clin Ther 1996; 18 (3): 546-58
49. Jacobson MA, Drew WL, Feinberg J, et al. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis 1991; 163 (6): 1348-51
50. Fanning MM, Read SE, Benson M, et al. Foscarnet therapy of cytomegalovirus retinitis in AIDS. J Acquir Immune Defic Syndr 1990; 3: 472-9
51. Katlama C, Dohin E, Caumes E, et al. Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times daily regimens. J Acquir Immune Defic Syndr 1992; 5 Suppl. 1: S18-S24
52. Carosi G, Castelli F, Lernestedt JO, et al. Convenient twice daily foscarnet in induction therapy of AIDS-associated cytomegalovirus retinitis. AIDS 1997; 11 (2): 258-60
53. Jacobson MA, JJ OD, Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother 1989; 33 (5): 736-41
54. Chrisp P, Clissold SP. Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 1991; 41 (1): 104-29
55. Polis MA, Desmet MD, Baird BF, et al. Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (Foscarnet). Am J Med 1993; 94: 175-80
56. Jacobson MA, Causey D, Polsky B, et al. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J Infect Dis 1993; 168: 444-8
57. Drusano GL, Aweeka F, Gambertoglio J, et al. Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients. AIDS 1996; 10: 1113-9
58. Walmsley SL, Chew E, Read SE, et al. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate (Foscarnet). J Infect Dis 1988; 157 (3): 569-72
59. Deray G, Katlama C, Dohin E. Prevention of foscarnet nephrotoxicity [letter]. Ann Intern Med 1990; 113 (4); 332
60. Benson P, Nahass R, Dereskinski S, et al. Safety of oral vs. intravenous hydration during induction therapy with intravenous foscavir in AIDS patients with CMV infections [abstract 299]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington (DC): 119
61. Farese Jr RV, Schambelan M, Hollander H, et al. Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis. Ann Intern Med 1990; 112 (12): 955-6
62. Jacobson MA, Wulfsohn M, Feinberg JE, et al. Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG Protocol 093). AIDS 1994; 8: 451-9
63. Gearhart MO, Sorg TB. Foscarnet-induced severe hypomagnesemia and other electrolyte disorders. Ann Pharmacother 1993; 27: 285-9
64. Jacobson MA, Gamberloglio JG, Aweeka FT, et al. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J Clin Endocrinol Metab 1991; 72: 1130-5
65. Jayaweera DT, White G, Moreno J. Pre-treatment with hydration and electrolytes may prevent dose limiting toxicities during foscarnet induction therapy. Genitourin Med 1995; 71: 414-5
66. Youle MS, Clarbour J, Gazzard B, et al. Severe hypocalcemia in AIDS patients treated with foscarnet and pentamidine [letter]. Lancet 1988; 1: 1455-6
67. Gilquin J, Weiss L, Kazatchkine MD. Genital and oral erosions induced by foscarnet [letter]. Lancet 1990; 335: 287
68. Van der Pijl JW, Frissen PHJ, Reiss P, et al. Foscarnet and penile ulceration [letter]. Lancet 1990; 335: 286
69. Fegueux S, Salmon D, Picard C, et al. Penile ulcerations with foscarnet [letter]. Lancet 1990; 335: 547
70. Moyle G, Nelson M, Barton SE, et al. Penile ulcerations with foscarnet [letter]. Lancet 1990; 335: 547-8
71. Lernestedt JO, Chanas AC. Penile ulcerations with foscarnet [letter]. Lancet 1990; 335: 548
72. Singhal BS, Lalkaka SA, Sonoda S, et al. Penile ulceration with foscarnet therapy. AIDS 1993; 7: 140-1
73. Lacey HB, Ness A, Mandal BK. Vulval ulceration associated with foscarnet. Genitourin Med 1992; 68: 182
74. Gross AS, Dretler RH. Foscarnet-induced penile ulcer in an uncircumcised patient with AIDS [letter]. Clin Infect Dis 1993; 17: 1076-7
75. Evans LM, Grossman ME. Foscarnet-induced penile ulcer. J Am Acad Dermatol 1992; 27 (1): 124-6
76. Manischewitz JF, Quinnan GVJ, Lane HC, et al. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1990; 34: 373-5
77. Jacobson MA, Kramer F, Bassiakos Y, et al. Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151. J Infect Dis 1994; 170 (1): 189-93
78. Kuppermann BD, Flores-Aguilar M, Quiceno JI, et al. Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Arch Ophthalmol 1993; 111 (10): 1359-66
79. Geier SA, Klauss V, Matuschke A, et al. 2.5 years survival with sequencial ganciclovir/foscarnet treatment in a patient with acquired immune deficiency syndrome and cytomegalovirus retinitis. Ger J Ophthalmol 1992; 1 (2): 110-3
80. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: The Cytomegalovirus Retreatment Trial. Arch Ophthalmol 1996; 114 (1): 23-33
81. Dega H, Eliaszewica M, Gisselbrecht M, et al. Infections associated with totally inplantable venous access devices (TIVAD) in human immunodeficiency virus-infected patients. J Acquir Immune Defic Syndr 1996; 13: 146-54
82. Moore DAJ, Gazzard GB, Nelson MR. Central venous line infections in AIDS. J Infection 1997; 34: 35-40
83. Van der Pijl H, Jos Frissen PH. Experience with a totally implantable venous access device (Port-A-Cath) in patients with AIDS. AIDS 1992; 6: 709-13
84. Henry K, Thurn JR, Johnson S. Experience with central venous catheters in patients with AIDS [letter]. N Engl J Med 1989; 320: 1496
85. Raviglione MC, Battan R, Pablos-Mendez A, et al. Infections aasociated with Hickman catheters in patients with acquired immunodeficiency syndrome. Am J Med 1989; 86: 780-6
86. Prichard JG, Nelson MJ, Burns L, et al. Infections caused by central venous catheters in patients with acquired immunodeficiency syndrome. South Med J 1988; 81: 1496-8
87. Skoutelis AT, Murphy RL, MacDonell KB, et al. Indwelling central venous catheter infections in patients with acquired immune deficiency syndrome. J Acquir Immune Defic Syndr 1990; 3 (4): 335-42
88. Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: a randomized, controlled trial. Ann Intern Med 1997; 126 (4): 257-63
89. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. Ann Intern Med 1997; 126: 264-74
90. Lalezari JP, Drew WL, Glutzer E, et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995; 171 (4): 788-96
91. Davis JL, Taskintuna I, Freeman WR, et al. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997; 115 (6): 733-7
92. Palau LA, Tufty GT, Pankey GA. Recurrent iritis after intravenous administration of cidofovir. Clin Infect Dis 1997; 25 (2): 337-8
93. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol 1994; 112 (12): 1531-9
94. Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med 1997; 337 (2): 83-90
95. Stalder N, Sudre P, Olmari M, et al. Cytomegalovirus retinitis: decreased risk of bilaterality with increased use of systemic treatment. Clin Infect Dis 1997; 24: 620-4
96. Anand R, Nightinglage SD, Fish RH, et al. Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir: long term results. Arch Ophthalmol 1993; 111: 223-7
97. Duker JS, Robinson M, Anand R, et al. Initial experience with an eight-month sustained-release intravitreal ganciclovir implant for the treatment of CMV retinitis associated with AIDS. Ophthalmic Surg Lasers 1995; 26 (5): 442-8
98. Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patient for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N Engl J Med 1999; 340: 1063-70
99. Martin DF, Dunn JP, Davis JL, et al. Use of the ganciclovir implant for the treatment of CMV retinitis in the era of potent antiretroviral therapy. Recommendations of the IAS-USA panel. Am J Ophthamol 1999; 127 (3): 329-39
100. Jabs DA, Enger C, Haller J, et al. Retinal detachments in patients with cytomegalovirus retinitis. Arch Ophthalmol 1991; 109: 794-9
101. Freeman WR, Friedberg DN, Berry C, et al. Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis. Am J Ophthalmol 1993; 116: 713-20
102. Henry K, Cantrill H, Fletcher C, et al. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 1987; 103 (1): 17-23
103. Cantrill HL, Henry K, Melroe NH, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results. Ophthalmology 1989; 96: 367-74
104. Ussery FMI, Gibson SR, Conklin RH, et al. Intravitreal ganciclovir in the treatment of AIDS associated cytomegalovirus retinitis. Ophthalmology 1988; 95: 640-8
105. Heinemann MH. Long-term intravitreal ganciclovir treatment of cytomegalovirus retinopathy. Arch Ophthalmol 1989; 107: 1767-72
106. Cochereau-Massin I, Lehoang P, Lautier-Frau M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1991; 98: 1348-55
107. Baudouin C, Chassain C, Caujolle C, et al. Treatment of cytomegalovirus retinitis in AIDS patients using intravitreal injection of highly concentrated ganciclovir. Ophthalmologica 1996; 210 (6): 329-35
108. Hodge WG, Lalonde RG, Sampalis J, et al. Once-weekly intraocular injections of ganciclovir for maintenance therapy of cytomegalovirus retinitis: clinical and ocular outcome. J Infect Dis 1996; 174 (2): 393-6
109. Melchior WR, Bindlsih V, Rybak MJ. Intravitreal ganciclovir for cytomegalovirus retinitis in AIDS patients. Ann Pharmacother 1992; 26: 36-7
110. Lieberman RM, Orellana J, Melton RC. Efficacy of intravitreal foscarnet in a patient with AIDS [letter]. N Engl J Med 1994; 330 (12): 868-9
111. Tognon MS, Turrini B, Masiero G, et al. Intravitreal and systemic foscarnet in the treatment of AIDS-relatcd CMV retinitis. Eur J Ophthalmol 1996; 6 (2): 179-82
112. Diaz-Llopis M, Espana F, Munoz G, et al. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. Br J Ophthalmol 1994; 78 (2): 120-4
113. Kirsch LS, Arevalo JF, Chavez de la Paz E, et al. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome [discussion 542-3]. Ophthalmology 1995; 102 (4): 533-42
114. Kirsch LS, Arevalo JF, De Clereq E, et al. Phase I/Il study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1995; 119 (4): 466-76
115. Rahhal FM, Arevalo JF, Munguia D, et al. Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis. Ophthalmology 1996; 103 (7): 1078-83
116. Banker AS, Arevalo JF, Munguia D, et al. Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis. Am J Ophthalmol 1997; 124 (2): 168-80
117. Rahhal FM, Arevalo JF, Chavez de la Paz E, et al. Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS: a preliminary report. Ann Intern Med 1996; 125 (2): 98-103
118. Chavez-de la Paz E, Arevalo JF, Kirsch LS, et al. Anterior non-granulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis: analysis and prevention. Ophthalmology 1997; 104 (3): 539-44
119. Taskintuna I, Rahhal FM, Rao NA, et al. Adverse events and autopsy findings after intravitreous cidofovir (HPMPC) therapy in patients with acquired immune deficiency syndrome (AIDS) [discussion 1836-7]. Ophthalmology 1997; 104 (11): 1827-36
120. Brown F, Arum I, Francis G, et al. Ganciclovir prodrug (RS79070): multiple dose, dose-ranging study with effect of food [abstract LB-19]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington (DC): 209
121. Naesens L, Snoeck R, Andrei G, et al. HPMPC (cidofovir), PMEA (adefovir) and related acyclic-nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem Chemother 1997; 8: 1-23
122. Cherrington JM, Fuller MD, Chen MS. Antiviral effects of adefovir (PMEA) against in vitro replication of wild type and drug resistant human cytomegalovirus (HCMV) clinical isolates. 3rd International Congress on Drug Therapy in HIV Infection; 1996 Nov 3-7; Birmingham: 9
123. Kahn J, Lagakos S, Weng D, et al. A multicenter, randomized, double-blind placebo controlled study of the efficacy and safety of adefovir dipivoxil (Adv) when added to standard antiretroviral therapy (Art) [abstract 1-108]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego (CA): 396
124. Barditch-Crovo P, Toole J, Hendrix CW, et al. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis 1997; 176 (2): 406-13
125. Decks SG, Collier A, Lalezari J, et al. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis 1997; 176 (6): 1517-23
126. Tenney DJ, Yamanaka O, Voss SM, et al. Lobucavir is phosphorylated in human cytomegalovirus infected and -uninfected cells and inhibits the viral DNA polymerase. Antimicrob Agents Chemother 1997; 41 (12): 2680-5
127. Flaherty J, Lalezari J, Petty B, et al. Pharmacokinetics and safety of oral lobucavir in cytomegalovirus-infected HIV patients [abstract 302]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington (DC): 120
128. Lalezari J, Drew W, Jordan C, et al. In vivo anti-CMV activity and safety of oral lobucavir in HIV-infected patients [abstract 301]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington (DC.): 120
129. Biron KK, Davis MG, Stanat SC, et al. Antiviral activity and mechanism of action of 1263 W94, a benzimidazole riboside inhibitor of human cytomegalovirus [abstract H085]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18; New Orleans: 178
130. Lalezari JP, Aberg JA, Wang LH, et al. In vivo anti-CMV activity, safety and pharmacokinetics of oral 1263W94 in HIV-infected subjects with asymptomatic CMV shedding [abstract 762]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago (IL): 221
131. Wang LH, Lyogendran S, Weller S, et al. A phase I trial evaluating the tolerability and pharmacokinetics of 1263W94 following single oral administration of escalating doses in normal healthy volunteers [abstract H028]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18; New Orleans (LA): 168
132. Askari FK, McDonnell WM. Antisense-oligonucleotide therapy. N Engl J Med 1996; 334 (5); 316-8
133. Lieberman RM, Orellana J. Safety and efficacy of fomivirsen sodium (ISIS 2922) for CMV retinitis in AIDS patients [abstract 308]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington (DC): 121
134. Flores-Aguilar M, Besen G, Vuong C, et al. Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015. J Infect Dis 1997; 175 (6): 1308-16
135. Muccioli C, Goldstein DA, Johnson DW, et al. Fomivirsen safety and efficacy in the treatment of CMV retinitis: a phase 3, controlled, multicenter study comparing immediate versus delayed treatment [abstract LB-6]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago (IL): 224
136. Hutcherson SL, Palestine AG, Cantrill HL, et al. Antisense oligonucleotide safety and efficacy for CMV retinitis in AIDS patients [abstract H-136]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco: 204
137. Palella FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med 1998; 338 (13): 853-60
138. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres: Federation National des Centres de Lutte contre le SIDA. AIDS 1997; 11 (12): F101-5
139. Selik RM, Karon JM, Ward JW. Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993. J Infect Dis 1997; 176 (3): 632-6
140. Hogg RS, MV OS, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals [letter]. Lancet 1997; 349 (9061): 1294
141. Chiller T, Park A, Chiller K, et al. HIV protease inhibitor therapy is associated with increased time to relapse and death in AIDS patients with cytomegalovirus retinitis [abstract I-267.]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sept 24-27; San Diego (CA): 448
142. Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998; 4(8): 953-6